Worldwide Huntington's Disease Industry to 2029 - A Robust Product Pipeline of Disease-Modifying Treatments is Expected to Drive the Market - ResearchAndMarkets.com

15 Nov 2022
www.businesswire.com
DUBLIN--(BUSINESS WIRE)--The "Huntington's Disease Market Analysis by Treatment (Disease-modifying Therapies, Symptomatic Treatment) and by Region - Global Forecast to 2029" report has been added to ResearchAndMarkets.com's offering.
'Huntington\'s Disease Market Analysis by Treatment (Disease-modifying Therapies, Symptomatic Treatment) and by Region - Global Forecast to 2029'
The Hutington's Disease market size is estimated to be USD 475.3 million in 2021 and is expected to witness a CAGR of 21.61% during the forecast period 2022-2029.
Ingrezza's expected label expansion for treating chorea associated with Huntington's disease, the high prevalence of HD in Western countries, and a robust product pipeline of disease-modifying treatments is expected to drive the market. However, low success rate in clinical trials is expected to restrain the market growth.
Segmentation: Hutington's Disease Market Report 2021-2029
By Treatment (Revenue, USD Million)
Disease-modifying Therapies
Symptomatic Treatment
By Region (Revenue, USD Million)
North America
U.S
Canada
Europe
Germany
France
UK
Spain
Italy
Rest of Europe
China
Japan
India
Australia
South Korea
Rest of APAC
Latin America
Brazil
Mexico
Argentina
Rest of LATAM
Middle East & Africa
South Africa
GCC
Rest of MEA
Companies Mentioned
Teva (Israel)
Novartis AG (Switzerland)
GSK (UK)
AbbVie (US)
Merck (US)
Lundbeck (Denmark)
UCB (Belgium)
Acadia (US)
Sun Pharma (India)
Wockhardt (India)
Dr. Reddy's (India)
Intas (India)
US WorldMeds (US)
Zydus Cadila (India)
Cipla (India)
Strides (India)
1 A Pharma (India)
Upsher-Smith (US)
For more information about this report visit https://www.researchandmarkets.com/r/aboj38
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-
Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.